Insulet Corporation (PODD) — 分析摘要
Insulet Corporation（PODD）的市值为9.95十亿美元，最近一年的营收同比增长了+30.7%。净利润率为9.1%。当前市盈率为26.5倍。
核心要点
- 营收同比变化+30.7%
- 净利润率9.1%
- 市盈率26.5倍
与SURGICAL & MEDICAL INSTRUMENTS & APPARATUS板块的其他公司相比，PODD的营收增长为+30.7%，市盈率为26.5倍。
Insulet Corporation (PODD)
更新 — ET · 市场数据 POLYGON · 财务数据 SEC EDGAR
红旗与风险提示无重大红旗
基于最新财报，没有触发重大的信用、利润率或趋势红旗。
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.
行业
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
员工人数
5,400
总部
ACTON, MA
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。